{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:26:57Z","timestamp":1776482817932,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.01.075","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T02:51:24Z","timestamp":1614307884000},"page":"1773-1779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes"],"prefix":"10.1016","volume":"39","author":[{"given":"Jay A.","family":"Spencer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8819-8039","authenticated-orcid":false,"given":"Tom","family":"Penfound","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanaz","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle P.","family":"Aranha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Baudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.01.075_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","author":"Carapetis","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.075_b0010","doi-asserted-by":"crossref","DOI":"10.1136\/jcp.46.7.617","article-title":"Rapidly fatal necrotising fasciitis caused by Streptococcus pyogenes","author":"Donaldson","year":"1993","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.vaccine.2021.01.075_b0015","doi-asserted-by":"crossref","DOI":"10.3201\/eid0103.950301","article-title":"Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment","author":"Stevens","year":"1995","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.075_b0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1603693","article-title":"Global, regional, & national burden of rheumatic heart disease, 1990\u20132015","author":"Watkins","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.01.075_b0025","unstructured":"JDale JB, Batzloff MR, Cleary PP, Courtney HS, Good MF, Grandi G, et al. Current approaches to group A streptococcal vaccine development; 2016."},{"key":"10.1016\/j.vaccine.2021.01.075_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198658","article-title":"Evaluation of safety and immunogenicity of a group a streptococcus vaccine candidate (mj8vax) in a randomized clinical trial","author":"Sekuloski","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.01.075_b0035","doi-asserted-by":"crossref","DOI":"10.1001\/jama.292.6.709","article-title":"Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: Phase 1 trial","author":"Kotloff","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2021.01.075_b0040","doi-asserted-by":"crossref","unstructured":"McNeil S a, Halperin S a, Langley JM, Smith B, Warren A, Sharratt GP, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005. https:\/\/doi.org\/10.1086\/444458.","DOI":"10.1086\/444458"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.075_b0045","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.12.005","article-title":"Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study","volume":"38","author":"Pastural","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.075_b0050","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu260","article-title":"A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development","author":"Sanderson-Smith","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.075_b0055","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix599","article-title":"Immune cross-opsonization within emm clusters following group A streptococcus skin infection: broadening the scope of type-specific immunity","author":"Frost","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.075_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.11.065","article-title":"Structure-based design of broadly protective group a streptococcal M protein-based vaccines","author":"Dale","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.075_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/nmicrobiol.2016.155","article-title":"Conserved patterns hidden within group A Streptococcus M protein hypervariability recognize human C4b-binding protein","author":"Buffalo","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2021.01.075_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003323","article-title":"Factor H binds to the hypervariable region of many streptococcus pyogenes M proteins but does not promote phagocytosis resistance or acute virulence","author":"Gustafsson","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.01.075_b0075","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA119.011258","article-title":"Structure-based group A streptococcal vaccine design: helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides","author":"Aranha","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2021.01.075_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/0264-410X(93)90042-V","article-title":"Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors","author":"Zheng","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.075_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2016.86","article-title":"An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene","author":"Sun","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2021.01.075_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2004.05.028","article-title":"High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity","author":"Liu","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.075_b0095","doi-asserted-by":"crossref","DOI":"10.1002\/prot.21078","article-title":"Prediction of continuous B-cell epitopes in an antigen using recurrent neural network","author":"Saha","year":"2006","journal-title":"Proteins Struct Funct Genet"},{"key":"10.1016\/j.vaccine.2021.01.075_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-8-361","article-title":"Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines","author":"Bui","year":"2007","journal-title":"BMC Bioinf"},{"key":"10.1016\/j.vaccine.2021.01.075_b0105","doi-asserted-by":"crossref","DOI":"10.1128\/iai.65.9.3913-3923.1997","article-title":"Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein","author":"Cunningham","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.01.075_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/S0264-410X(98)00150-9","article-title":"Multivalent group a streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments","author":"Dale","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.075_b0115","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.72.5.2507-2512.2004","article-title":"Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections","author":"Hall","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.01.075_b0120","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00617-18","article-title":"Development of an opsonophagocytic killing assay using HL-60 cells for detection of functional antibodies against streptococcus pyogenes","author":"Salehi","year":"2018","journal-title":"MSphere"},{"key":"10.1016\/j.vaccine.2021.01.075_b0125","unstructured":"Salie Tariq, Engel M. Rapid Review of Global Emm Types 2020. (Accessed October 27, 2020) https:\/\/doi.org\/10.25375\/uct.13056074.v1."},{"key":"10.1016\/j.vaccine.2021.01.075_b0130","doi-asserted-by":"crossref","DOI":"10.1084\/jem.163.5.1191","article-title":"Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein","author":"Dale","year":"1986","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.01.075_b0135","doi-asserted-by":"crossref","DOI":"10.1084\/jem.166.3.647","article-title":"Protective immunogenicity and T lymphocyte specificity of a trivalent hybird peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem","author":"Beachey","year":"1987","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.01.075_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2011.09.005","article-title":"New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci","author":"Dale","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.075_b0145","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.70.4.2171-2177.2002","article-title":"Immunogenicity of a 26-valent group A streptococcal vaccine","author":"Hu","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.01.075_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2010.05.018","article-title":"Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes","author":"Penfound","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.075_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(09)70178-1","article-title":"Global emm type distribution of group A streptococci: systematic review and implications for vaccine development","author":"Steer","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.075_b0160","doi-asserted-by":"crossref","DOI":"10.1084\/jem.150.4.862","article-title":"Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal m protein","author":"Beachey","year":"1979","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.01.075_b0165","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00101-13","article-title":"Disease manifestations and pathogenic mechanisms of group A Streptococcus","author":"Walker","year":"2014","journal-title":"Clin Microbiol Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:54:36Z","timestamp":1759402476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21001298"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}